Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 17/20 | 1.00 |
| ▸ | GBA1 | P04062 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | UGCG | Q16739 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17189564 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL17243607 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL3324203 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL13175020 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL6821239 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL13253278 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL3020875 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL2268575 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL2789051 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL9797495 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | claimed |
| EP-4646931-A9 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | Francisco Aragon S.L.U (ES) | 2025-12-24 | — | — | EP | disclosed |
| EP-4646931-A1 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | Francisco Aragon S.L.U (ES) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025047983-A1 | NOVEL PRODRUG-TYPE ANTICANCER AGENT TARGETING CANCER-SPECIFIC ENZYME ACTIVITY | 国立大学法人 東京大学 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024089310-A1 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | FRANCISCO ARAGÓN S.L.U (ES) | 2024-05-02 | — | — | WO | disclosed |
| EP-4106752-A2 | TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS | Florida State University Research Foundation, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220339140-A1 | TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11369592-B2 | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-10561642-B2 | Treatment of Zika virus infections using alpha-glucosidase inhibitors | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10328061-B2 | Treatment of Zika virus infections using alpha-glucosidase inhibitors | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2017192599-A1 | TREATMENT OF ZIKA VIRUS INFECTIONS USING ALPHA-GLUCOSIDASE INHIBITORS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170312257-A1 | TREATMENT OF ZIKA VIRUS INFECTIONS USING ALPHA-GLUCOSIDASE INHIBITORS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9199935-B2 | Pharmaceutically active piperidine derivatives | Acetelion Pharmaceuticals Ltd. (CH) | 2015-12-01 | — | — | US | disclosed |
| US-9199935-B2 | Pharmaceutically active piperidine derivatives | Acetelion Pharmaceuticals Ltd. (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20140303208-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140303208-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-10-09 | — | — | US | disclosed |
| US-8729099-B2 | Pharmaceutically active piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-20 | — | — | US | disclosed |
| US-8729099-B2 | Pharmaceutically active piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-20 | — | — | US | disclosed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | disclosed |
| EP-1362031-B1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303208-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES | GBA1, GBA2, UGCG | GBA2 2/4885GBA1 1/4885GAA 11/4885 |
| US-11369592-B2 | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | ACE2, ACE, GAA | GBA2 114/4885GBA1 56/4885GAA 3/4885 |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | GBA2 4/4885GBA1 1/4885GAA 11/4885 |
| US-20220339140-A1 | TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS | ACE2, ACE, GAA | GBA2 114/4885GBA1 56/4885GAA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.